Tebentafusp: a first-in-class treatment for metastatic uveal melanoma

Tebentafusp is a first-in-class immunotherapy agent that comprises an engineered T-cell receptor targeting a gp100 epitope presented by human leukocyte antigen-A*02:01 cells, fused to an anti-CD3 single-chain variable fragment. Tebentafusp is both the first bispecific T-cell engager to show efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales: Howlett, Sarah, Carter, Thomas J., Shaw, Heather M., Nathan, Paul D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10031621/
https://www.ncbi.nlm.nih.gov/pubmed/36970111
http://dx.doi.org/10.1177/17588359231160140
_version_ 1784910646293299200
author Howlett, Sarah
Carter, Thomas J.
Shaw, Heather M.
Nathan, Paul D.
author_facet Howlett, Sarah
Carter, Thomas J.
Shaw, Heather M.
Nathan, Paul D.
author_sort Howlett, Sarah
collection PubMed
description Tebentafusp is a first-in-class immunotherapy agent that comprises an engineered T-cell receptor targeting a gp100 epitope presented by human leukocyte antigen-A*02:01 cells, fused to an anti-CD3 single-chain variable fragment. Tebentafusp is both the first bispecific T-cell engager to show efficacy in the treatment of advanced solid cancer and the first anti-cancer treatment to demonstrate an overall survival benefit in patients with uveal melanoma (UM). This review article will focus on the clinical development of tebentafusp, the mechanism of action and resultant evolution of the management of advanced UM.
format Online
Article
Text
id pubmed-10031621
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-100316212023-03-23 Tebentafusp: a first-in-class treatment for metastatic uveal melanoma Howlett, Sarah Carter, Thomas J. Shaw, Heather M. Nathan, Paul D. Ther Adv Med Oncol Review Tebentafusp is a first-in-class immunotherapy agent that comprises an engineered T-cell receptor targeting a gp100 epitope presented by human leukocyte antigen-A*02:01 cells, fused to an anti-CD3 single-chain variable fragment. Tebentafusp is both the first bispecific T-cell engager to show efficacy in the treatment of advanced solid cancer and the first anti-cancer treatment to demonstrate an overall survival benefit in patients with uveal melanoma (UM). This review article will focus on the clinical development of tebentafusp, the mechanism of action and resultant evolution of the management of advanced UM. SAGE Publications 2023-03-21 /pmc/articles/PMC10031621/ /pubmed/36970111 http://dx.doi.org/10.1177/17588359231160140 Text en © The Author(s), 2023 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Review
Howlett, Sarah
Carter, Thomas J.
Shaw, Heather M.
Nathan, Paul D.
Tebentafusp: a first-in-class treatment for metastatic uveal melanoma
title Tebentafusp: a first-in-class treatment for metastatic uveal melanoma
title_full Tebentafusp: a first-in-class treatment for metastatic uveal melanoma
title_fullStr Tebentafusp: a first-in-class treatment for metastatic uveal melanoma
title_full_unstemmed Tebentafusp: a first-in-class treatment for metastatic uveal melanoma
title_short Tebentafusp: a first-in-class treatment for metastatic uveal melanoma
title_sort tebentafusp: a first-in-class treatment for metastatic uveal melanoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10031621/
https://www.ncbi.nlm.nih.gov/pubmed/36970111
http://dx.doi.org/10.1177/17588359231160140
work_keys_str_mv AT howlettsarah tebentafuspafirstinclasstreatmentformetastaticuvealmelanoma
AT carterthomasj tebentafuspafirstinclasstreatmentformetastaticuvealmelanoma
AT shawheatherm tebentafuspafirstinclasstreatmentformetastaticuvealmelanoma
AT nathanpauld tebentafuspafirstinclasstreatmentformetastaticuvealmelanoma

Ejemplares similares